PENTAX Medical Launches Innovative J10 Series Endoscopic Ultrasound Gastroscopes In the USA

September 15, 2020

PENTAX Medical has announced the launch of the new J10 Series Ultrasound Video Gastroscopes.

In assessing GI diseases, endoscopic ultrasound (EUS) is a minimally invasive and highly accurate procedure that uses high-frequency sound waves to produce detailed images of tissue and surrounding organs such as the pancreas and liver. While used primarily for diagnostic procedures such as EUS-guided Fine Needle Aspiration (EUS-FNA), EUS-guided Fine Needle Biopsy (EUS-FNB), and tumor staging, there has been a shift towards using EUS for interventional procedures and to treat pancreaticobiliary diseases as a less-invasive option than ERCP.

The new PENTAX Medical J10 Series Ultrasound Video Gastroscopes deliver on both clinical and market needs, offering ergonomic design, renowned image quality and enhanced maneuverability as an EUS solution.

With ultrasound gastroscopes, high functionality and performance are critical for success, given that indications are so varied. Designed for optimal procedural efficiency in EUS, the new J10 Series Ultrasound Video Gastroscopes provide a lightweight and ergonomic control body design to ensure stability and ease of intubation while reducing hand fatigue. With a proven PENTAX-Hitachi image quality to support visual certainty and diagnoses, the J10 Series produces greater detail, clearer delineation, and superior penetration. Additionally, maneuvering, device control, and instrument compatibility are augmented with shorter rigid distal section lengths, increased tip deflection, smaller bending radius and an enlarged working channel.

“With the immense success of the J10 Series endoscopes since their introduction in other global regions, we are now very pleased and excited for their introduction in the USA as well,” stated Gerald W. Bottero, Global President of PENTAX Medical. “With a focus on exceptional maneuverability and high-definition endoscopic imaging, the J10 Series provides an innovative solution for performing endoscopic evaluations, increasing diagnostic capabilities, and determining pathways for effective patient management.”

Specific enhancements with the new J10 Series Ultrasound Video Gastroscopes include increased linear scope scan angle of 150° for broader imaging, increased frequency (13MHz) for near-field exploration, widened depth of field range (3mm–100mm), increased angulations to optimize access in the GI tract, and sealed elevator wire channels to help reduce risk of cross-contamination. The EG38-J10UT also has an enlarged instrument channel width (4mm), expanding therapeutic capabilities to advance EUS-guided intervention while providing full control of the procedure.

The new J10 Series is really a step forward in the set-up and portfolio of endoscopic ultrasound,” said Dr. Paolo G. Arcidiacono, Ospedale San Raffaele, Milan, Italy. “It is a significant improvement on both the endoscopic and the endosonographic side. Particularly for therapeutic procedures, the improved endoscopic view has solved previous compromises.”

The J10 Series is commercially available now. An exclusive Virtual Launch Event is scheduled for October 14, 2020 at 6:00 PM EDT. Three renowned endoscopic ultrasound experts will present difficult EUS cases and discuss the potential benefits and differences of the new J10 Series lineup.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy